Medimmune is welcoming biotech firm Amplimmune to the AstraZeneca family in a deal that could be worth up to $500m for the Johns Hopkins University spin-out. Medimmune, the research and development unit of life sciences conglomerate AstraZeneca, acquired 100% of Amplimmune’s shares for an initial consideration of $225m. A further $275m is available based on…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
